+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Allergy Immunotherapy Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797847
The global allergy immunotherapy market size attained a value of USD 2 billion in 2022. The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2023-2031 to attain a value of USD 4.67 billion by 2031.

Allergy Immunotherapy Market: Introduction

Allergy immunotherapy is a type of treatment that is used to reduce the symptoms associated with allergies. This treatment involves exposing patients to small amounts of the allergen that triggers their allergy symptoms, gradually increasing the dose over time to build up their tolerance to the allergen.

Allergy immunotherapy is used to treat a wide range of allergies, including seasonal allergies, food allergies, and allergies to pet dander, dust mites, and insect venom. It is typically recommended for individuals who have moderate to severe allergy symptoms that are not effectively controlled with medications or avoidance of the allergen.

The benefits of allergy immunotherapy include long-term relief from allergy symptoms, a reduced need for allergy medications, and the potential to prevent the development of asthma in children with allergies.

Allergy immunotherapy is typically administered in the form of injections, sublingual drops or tablets, or oral immunotherapy. Immunotherapy injections involve injecting small amounts of the allergen under the skin, while sublingual drops or tablets are placed under the tongue. Oral immunotherapy involves ingesting small amounts of the allergen in gradually increasing doses.

Allergy immunotherapy is typically administered by an allergist or immunologist in a clinical setting. Patients undergoing immunotherapy require close monitoring for potential side effects, such as allergic reactions.

In summary, allergy immunotherapy is a type of treatment that is used to reduce the symptoms associated with allergies. It involves gradually exposing patients to small amounts of the allergen that triggers their allergy symptoms, with the goal of building up their tolerance to the allergen over time. Allergy immunotherapy is used to treat a wide range of allergies and is typically administered in the form of injections, sublingual drops or tablets, or oral immunotherapy. It is a long-term treatment option that offers relief from allergy symptoms and can reduce the need for allergy medications.

Allergy Immunotherapy Epidemiology
The prevalence of allergies is increasing globally, leading to a rise in the demand for allergy immunotherapy. Allergies affect individuals of all ages and genders and can be triggered by a variety of environmental factors and lifestyle habits.

Based on prevalence, the allergy immunotherapy market is segmented into seasonal allergies, perennial allergies, food allergies, and others. Seasonal allergies are the most common type of allergy, with a high prevalence of allergic rhinitis and hay fever during the spring and fall months. Perennial allergies, such as allergies to pet dander and dust mites, are also prevalent throughout the year. Food allergies are another common type of allergy, affecting individuals of all ages and leading to potentially life-threatening reactions in some cases.

Based on age, the allergy immunotherapy market is divided into children and adults. Allergies can develop at any age, with many individuals experiencing their first allergy symptoms during childhood. Children are a significant market for allergy immunotherapy, as early intervention with immunotherapy can prevent the development of asthma in children with allergies.

Based on gender, the allergy immunotherapy market is segmented into male and female. Allergies affect individuals of all genders, with certain types of allergies, such as food allergies, being more prevalent in females.

Based on lifestyle habits, the allergy immunotherapy market is divided into urban and rural populations. Urban populations are more likely to experience allergies, with exposure to air pollution and other environmental factors contributing to the development of allergies.

In summary, the allergy immunotherapy market is segmented based on prevalence, age, gender, and lifestyle habits. Allergies affect individuals of all ages and genders, and can be triggered by a variety of environmental factors and lifestyle habits. The allergy immunotherapy market is expected to grow in response to the increasing prevalence of allergies and the growing demand for safe and effective allergy treatments.

Allergy Immunotherapy Market Segmentations

The market can be categorised into treatment type, allergen type, treatment channel, distribution channel, region.

Market Breakup by Treatment Type

  • Subcutaneous Immunotherapy (SCIT)
  • Specific Immunotherapy (SIT)
  • Sublingual Immunotherapy (SLIT)
  • Sublingual Drops
  • Sublingual Tablets

Market Breakup by Allergen Type

  • Pollen Allergies
  • Grass Pollen
  • Tree Pollen
  • Weed Pollen
  • Food Allergies
  • Peanut Allergies
  • Tree Nut Allergies
  • Shellfish Allergies
  • Fish Allergies
  • Egg Allergies
  • Milk Allergies
  • Soy Allergies
  • Wheat Allergies
  • Others
  • Dust Mite Allergies
  • Mold Allergies
  • Animal Dander Allergies
  • Insect Venom Allergies

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by Distribution Channel

  • Direct Tenders
  • Retail Sales
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Allergy Immunotherapy Market Scenario

The global market for allergy immunotherapy is growing rapidly, driven by the increasing prevalence of allergies and the development of new and innovative treatments. Allergy immunotherapy is a long-term treatment option that offers relief from allergy symptoms and can reduce the need for allergy medications. It is typically recommended for individuals with moderate to severe allergy symptoms that are not effectively controlled with medications or avoidance of the allergen.

The market for allergy immunotherapy is highly competitive, with many players offering a wide range of products to cater to the diverse needs of healthcare providers and patients. The market is segmented based on product type, allergy type, distribution channel, and geography.

Based on product type, the market is divided into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). SCIT is the largest segment of the market, with a high demand for allergy shots that are administered in a clinical setting. SLIT involves the use of allergy drops or tablets that are placed under the tongue and can be taken at home.

Based on allergy type, the market is divided into seasonal allergies, perennial allergies, and food allergies. Seasonal allergies are the largest segment of the market, driven by the high prevalence of allergic rhinitis and hay fever during the spring and fall months.

Based on distribution channel, the market is divided into hospitals, specialty clinics, and pharmacies. Specialty clinics are the largest distribution channel segment of the market, owing to the high demand for allergy immunotherapy and the specialized care required for this treatment.

The market for allergy immunotherapy is expected to continue to grow at a steady pace, driven by the increasing prevalence of allergies and the growing demand for safe and effective allergy treatments. Advances in technology and research are expected to lead to the development of new and innovative treatments, which may provide more effective treatment options for patients with allergies.

Overall, the market for allergy immunotherapy is expected to continue to grow, driven by the increasing demand for safe and effective allergy treatments. Advances in technology and research are expected to lead to the development of new and innovative treatments, which may provide more effective treatment options for patients with allergies.

Key Players in the Global Allergy Immunotherapy Market

The report gives an in-depth analysis of the key players involved in the allergy immunotherapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • ALK-Abelló A/S
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Stallergenes Greer
  • Merck Group
  • HAL Allergy Group
  • DBV Technologies
  • Biomay AG
  • Anergis SA
  • Circassia Pharmaceuticals
  • Laboratorios LETI
  • HollisterStier Allergy
Frequently Asked Questions about the Global Allergy Immunotherapy Market

What is the estimated value of the Global Allergy Immunotherapy Market?

The Global Allergy Immunotherapy Market was estimated to be valued at $2.24 Billion in 2023.

What is the growth rate of the Global Allergy Immunotherapy Market?

The growth rate of the Global Allergy Immunotherapy Market is 9.6%, with an estimated value of $4.67 Billion by 2031.

What is the forecasted size of the Global Allergy Immunotherapy Market?

The Global Allergy Immunotherapy Market is estimated to be worth $4.67 Billion by 2031.

Who are the key companies in the Global Allergy Immunotherapy Market?

Key companies in the Global Allergy Immunotherapy Market include Alk, Abelló A/S, Allergy Therapeutics, Aimmune Therapeutics, Stallergenes Greer, Merck Group, Hal Allergy Group, Dbv Technologies, Biomay AG and Anergis Sa.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Allergy Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Allergy Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Allergy Epidemiology (2016-2031)
5.3 Europe Allergy Epidemiology (2016-2031)
5.4 Asia-Pacific Allergy Epidemiology (2016-2031)
5.5 Latin America Allergy Epidemiology (2016-2031)
5.6 Middle East & Africa Allergy Epidemiology (2016-2031)
6 Global Allergy Immunotherapy Market Overview
6.1 Global Allergy Immunotherapy Market Historical Value (2016-2022)
6.2 Global Allergy Immunotherapy Market Forecast Value (2023-2031)
7 Global Allergy Immunotherapy Market Landscape
7.1 Global Allergy immunotherapy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Allergy Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Allergan Type
7.2.3 Analysis by Distribution Channel
8 Allergy Immunotherapy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Allergy Immunotherapy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Allergy Immunotherapy Market Segmentation
11.1 Global Allergy Immunotherapy Market by Treatment Type
11.1.1 Market Overview
11.1.2 Subcutaneous Immunotherapy (SCIT)
11.1.3 Specific Immunotherapy (SIT)
11.1.4 Sublingual Immunotherapy (SLIT)
11.1.4.1 Sublingual Drops
11.1.4.2 Sublingual Tablets
11.2 Global Allergy Immunotherapy Market by Allergan Type
11.2.1 Market Overview
11.2.2 Pollen Allergies
11.2.2.1 Grass Pollen
11.2.2.2 Tree Pollen
11.2.2.3 Weed Pollen
11.2.3 Food Allergies
11.2.3.1 Peanut Allergies
11.2.3.2 Tree Nut Allergies
11.2.3.3 Shellfish Allergies
11.2.3.4 Fish Allergies
11.2.3.5 Egg Allergies
11.2.3.6 Milk Allergies
11.2.3.7 Soy Allergies
11.2.3.8 Wheat Allergies
11.2.3.9 Others
11.2.4 Dust Mite Allergies
11.2.5 Mold Allergies
11.2.6 Animal Dander Allergies
11.2.7 Insect Venom Allergies
11.3 Global Allergy Immunotherapy Market by Treatment Channel
11.3.1 Market Overview
11.3.2 Public
11.3.3 Private
11.4 Global Allergy Immunotherapy Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Direct Tenders
11.4.3 Retail Sales
11.4.4 Others
11.5 Global Allergy Immunotherapy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Allergy Immunotherapy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Allergy Immunotherapy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Allergy Immunotherapy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Allergy Immunotherapy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Allergy Immunotherapy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 ALK-Abelló A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergy Therapeutics
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Aimmune Therapeutics
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Stallergenes Greer
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Merck Group
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 HAL Allergy Group
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 DBV Technologies
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Biomay AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Anergis SA
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Circassia Pharmaceuticals
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Laboratorios LETI
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 HollisterStier Allergy
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Allergy Immunotherapy Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Alk-Abelló A/S
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Stallergenes Greer
  • Merck Group
  • Hal Allergy Group
  • Dbv Technologies
  • Biomay AG
  • Anergis Sa
  • Circassia Pharmaceuticals
  • Laboratorios Leti
  • Hollisterstier Allergy

Methodology

Loading
LOADING...